All of the following are true about muscarinic acetylcholine receptor antagonists EXCEPT:

## Analysis of Muscarinic Antagonists ### Correct Statements (Options 0, 1, 2) **Option 0: Atropine and mydriasis** - Atropine blocks M3 receptors on the iris sphincter muscle, preventing parasympathetic-mediated constriction - This results in unopposed sympathetic activity → mydriasis (pupil dilation) - This is a well-established clinical effect **Option 1: Scopolamine CNS penetration** - Scopolamine is more lipophilic than atropine due to its tropane structure - Greater lipophilicity → better blood–brain barrier penetration - Scopolamine causes more CNS effects (sedation, confusion) than atropine - This is why scopolamine is used for motion sickness (CNS H1 + M1 blockade) **Option 2: Ipratropium in asthma** - Ipratropium is a quaternary ammonium compound (charged, hydrophilic) - Poor systemic absorption from the respiratory tract - Remains localized to airways → bronchodilation without systemic anticholinergic effects - Preferred over atropine in asthma to avoid systemic toxicity ### Incorrect Statement (Option 3: Benztropine mechanism) **Key Point:** Benztropine does NOT enhance dopaminergic activity directly. It works by **reducing excessive cholinergic activity** in the basal ganglia. - In Parkinson's disease, dopamine is deficient and acetylcholine is relatively excessive - Benztropine blocks M1 muscarinic receptors in the basal ganglia - This **reduces cholinergic tone**, restoring the balance between dopamine and acetylcholine - Benztropine is a symptomatic agent — it does not increase dopamine levels - The statement incorrectly implies benztropine enhances dopaminergic activity, which is mechanistically false ## Clinical Pearl **Warning:** A common misconception is that anticholinergic drugs in Parkinson's disease work by increasing dopamine. In reality, they work by **decreasing cholinergic excess** relative to the deficient dopamine. This is why they are less effective than dopamine agonists or levodopa. ## High-Yield Summary Table | Drug | Structure | CNS Effect | Clinical Use | Key Feature | | --- | --- | --- | --- | --- | | Atropine | Tertiary amine | Moderate | Mydriasis, tachycardia, anticholinergic toxicity | Crosses BBB | | Scopolamine | Tertiary amine | High | Motion sickness, sedation | Most lipophilic | | Ipratropium | Quaternary ammonium | Minimal | Asthma/COPD | Poor systemic absorption | | Benztropine | Tertiary amine | Moderate | Parkinson's disease | Reduces cholinergic excess | [cite:KD Tripathi 8e Ch 6]